Tirbanibulin (Klisyri®): A Comprehensive Monograph on its Pharmacology, Clinical Efficacy, and Therapeutic Role in Dermatology

Executive Summary

Tirbanibulin is a first-in-class topical medication approved for the treatment of actinic keratosis (AK) on the face or scalp. Marketed under the brand name Klisyri®, it represents a significant advancement in dermatological therapy, distinguished by a novel, dual-action mechanism of action that inhibits both tubulin polymerization and Src kinase signaling.[1] This unique molecular activity allows for the targeted disruption of key pathways involved in the proliferation and survival of neoplastic keratinocytes characteristic of AK.[3]

The most notable clinical feature of Tirbanibulin is its remarkably short treatment duration, requiring only a once-daily application for five consecutive days.[5] This abbreviated regimen contrasts sharply with the weeks or months of therapy required for many established topical agents, addressing a critical unmet need for treatments that enhance patient adherence and satisfaction.[7] Its clinical profile is further defined by a favorable safety and tolerability profile. Adverse events are almost exclusively localized to the application site, consisting of predictable, transient, and manageable local skin reactions (LSRs) such as erythema and scaling, which typically resolve within a few weeks of treatment completion.[9]